Identification of patients at high risk for relapse by Merlin Assay (CP-GEP) in an independent cohort of patients with melanoma who did not undergo sentinel lymph node biopsy: head and neck subgroup analysis

• T. Amaral,
• E. Chatziioannou,
• A. Nuebling,
• T. Sinnberg,
• H. Niessner,
• U. Leiter,
• J. Dwarkasing,
• T. Arentsen,
• C. Groß,
• A. Eggermont,
• L. Flatz,
• S. Forchhammer

Affiliations

T. Amaral

Center for Dermatooncology, Eberhard Karls University of Tuebingen, Tuebingen, Germany; iFIT Cluster of Excellence, Tuebingen, Germany

E. Chatziioannou

iFIT Cluster of Excellence, Tuebingen, Germany; Department of Dermatology, Eberhard Karls University of Tuebingen, Tuebingen, Germany

A. Nuebling

Center for Dermatooncology, Eberhard Karls University of Tuebingen, Tuebingen, Germany

T. Sinnberg

Center for Dermatooncology, Eberhard Karls University of Tuebingen, Tuebingen, Germany; Skin Tumor Center Charité, Berlin, Germany

H. Niessner

Center for Dermatooncology, Eberhard Karls University of Tuebingen, Tuebingen, Germany; iFIT Cluster of Excellence, Tuebingen, Germany

U. Leiter

Center for Dermatooncology, Eberhard Karls University of Tuebingen, Tuebingen, Germany

J. Dwarkasing

SkylineDx BV, Rotterdam, The Netherlands

T. Arentsen

SkylineDx BV, Rotterdam, The Netherlands

C. Groß

SkylineDx BV, Rotterdam, The Netherlands

A. Eggermont

University Medical Center Utrecht & Princess Máxima Center, Utrecht, The Netherlands

L. Flatz

Department of Dermatology, Eberhard Karls University of Tuebingen, Tuebingen, Germany

S. Forchhammer

Department of Dermatology, Eberhard Karls University of Tuebingen, Tuebingen, Germany